Study On The Construction Of Targeted Enoxacin Sustained-release Body And Its Prevention And Treatment Of Bone Loss In Mice

Objective:Osteoporotic drugs not only play the role of anti-osteoporosis,but also often bring a series of adverse reactions,and the use of targeted drugs can well reduce the incidence of adverse reactions.For this reason,we constructed a targeted enoxacin sustainedrelease body(hereinafter referred to as sustained-release body),and designed a series of experiments to verify the effect of sustained-release body on bone loss in mice.Methods:1?Enoxacin was loaded on mesoporous silica nanoparticles and grafted with ASP-8 bone-targeted groups to construct enoxacin sustained-release bodies, and then the enoxacin release properties of the sustained-release bodies were measured.2?The range of cytotoxicity of sustained-release bodies was verified by CCK-8 test,and then the cells were cultured with different concentrations of sustained-release bodies to verify the effects of sustained-release bodies on the proliferation and differentiation of osteoclasts.3?Through the establishment of mouse osteoporosis model,different concentrations of sustained-release body and enoxacin powder were injected and compared with the control group to verify the effect of sustained-release body on bone loss in mice.Results:1?The release rate of enoxacin from sustained release body gradually slowed down with the passage of time.2?The sustained-release body did not produce cytotoxicity when the concentration was lower than 10ug/ml,and could significantly inhibit the proliferation and differentiation of osteoclasts.3?High-dose(8mg/kg)sustained-release body can significantly inhibit bone loss in bone and has no toxicity to liver and kidney.Conclusion:The sustained-release body we constructed can significantly inhibit the formation and differentiation of osteoclasts and inhibit bone loss in mice.